From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Pregabalin Is Effective for Treatment of Fibromyalgia

Patients who received pregabalin had significant improvements in pain and sleep.

Pregabalin, an amino acid that is structurally similar to the neurotransmitter {gamma}-aminobutyric acid, has analgesic, anticonvulsant, and anxiolytic properties. Small studies of very short duration suggest that pregabalin is effective for treatment of fibromyalgia.

In a multicenter randomized U.S. study, 748 patients with fibromyalgia received either placebo or pregabalin at daily doses of 300, 450, or 600 mg for 13 weeks. Before study entry, patients were required to discontinue almost all medicines (except acetaminophen) that could affect the outcomes measured. Compared with placebo recipients, patients treated at all dose levels of pregabalin had significant improvements in pain, sleep, and overall impression of symptoms. In general, improvements were greatest in the highest-dose group. Dizziness and somnolence were reported significantly more often by patients who received pregabalin, but the symptoms only rarely were severe enough to lead to discontinuation of the drug.

Comment: These results convincingly show that pregabalin is superior to placebo in the treatment of fibromyalgia, at least during the course of 13 weeks. The study could not determine whether pregabalin is superior to other therapies of proven benefit, such as tricyclic drugs, and whether the benefits extend beyond 13 weeks.

Anthony L. Komaroff, MD

Published in Journal Watch General Medicine May 27, 2008

Citation(s):

Mease PJ et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008 Mar; 35:502.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2008. Massachusetts Medical Society. All rights reserved.